• Follow-up purchase order for mass manufacture of branded products incorporating Audeara technology
• Material Purchase Order valued at US$917,000 (A$1.48m), following initial A$2.1m PO in 2024
• Validation of the use-case and saleability of Audeara's healthy hearing technology

Audeara Limited (ASX:AUA) is pleased to announce another significant milestone in the growth of the AUA Technology business unit, following receipt of the first follow-on purchase order (PO) with one of its international commercial partners, a large music instrument manufacturer. The combined orders mark a substantial step forward in Audeara's strategy to expand its technology licensing division, which has the capacity to scale across global markets with minimal capital expenditure or sales & marketing costs. The second order from Avedis Zildjian is valued at US$917,000, further solidifying the commercial potential of the collaboration following the initial A$2.1 million PO in 2024. The timing and scale of any further orders will be determined by the product's market performance, with Audeara remaining focused on leveraging its proprietary technology for long-term commercial success. The revenue from this purchase order will be recognised in accordance with accounting policies after shipment of the products. The purchase order adds to a growing pipeline of international sales and commercial integration partnerships for the group's AUA Technology division, following the formal launch of Clinico Sound Earbuds CS1 in the Taiwan market - a co-branded product integrating Audeara technology with Clinico Inc., Taiwan's largest hearing aid retailer.

The ongoing growth of the high-margin AUA Technology division is expected to be an important driver of the Company's path to cashflow breakeven and profitability.